logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2018 – Adding ribociclib to fulvestrant maintains quality of life in advanced breast cancer

Health-related quality of life (HRQoL) outcomes from the MONALEESA-3 trial demonstrate that patients don’t have to suffer more to achieve prolonged progression-free survival.